1. ¹Service d'Hématologie et d'Oncologie Médicale, CHU Montpellier, avenue du Doyen Giraud, Montpellier Cédex, France
2. ²Unité de Thérapie Cellulaire et Génique, Hôpital Saint-Eloi, CHU Montpellier, Avenue Augustin Fliche, Montpellier Cédex, France
3. ³Unité de Biostatistique, d'épidémiologie et de recherche clinique, avenue du Doyen Giraud, Montpellier Cédex, France
4. ⁴Diaclone Research, boulevard Alexandre Flemming, Besançon Cédex, France

Correspondence: Dr J-F Rossi, Service d'Hématologie et d'Oncologie Médicale, CHU Montpellier, 375, avenue du Doyen Giraud, 34295 Montpellier Cédex 05, France. E-mail: jf-rossi@chu-montpellier.fr

Received 18 February 2005; Accepted 1 July 2005; Published online 22 August 2005.

Abstract

Interleukin-6 (IL-6) is a major survival factor for multiple myeloma (MM) cells preventing apoptosis induced by dexamethasone (DEX) or chemotherapy. In all, 24 consecutive patients with MM in first-line therapy received DEX for 4 days, followed by melphalan (HDM: 140 mg/m²) and autologous stem cell transplantation (ASCT). The anti-IL-6 monoclonal antibody (mAb) (B-E8) was given till haematological recovery, starting 1 day before DEX. Results were historically compared to MM patients treated with HDM 140 and 200 mg/m². Our results show (1) that B-E8 was able to fully neutralize IL-6 activity in vivo before and after HDM as shown by inhibition of C reactive protein (CRP) production; (2) no haematological toxicity; (3) a significant reduction of mucositis and fever; (4) a median event-free survival of 35 months and an overall survival of 68.2% at 5 years with a median follow-up of 72 months; and (5) the overall daily IL-6 production progressively increased on and after 7 days post-HDM, with the increased serum CRP levels. In the 5/24 patients with uncontrolled CRP production, a large IL-6 production was detected (320 g/day) that could not possibly be neutralized by B-E8. These data show the feasibility to neutralize IL-6 in vivo with anti-IL-6 mAb in the context of HDM.